Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
Condition:   Prostate Cancer
Intervention:   Drug: [18F]-DCFPyl Ligand
Sponsors:   Stony Brook University;   Progenics Pharmaceuticals, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 13, 2020 / by / in
Comments